Roche appreciates 5.8% on promising oral anti-obesity data
NEWS. Roche finished Wednesday 5.8% up, corresponding to more than USD 16 billion in market cap, after disclosing Phase 1 data from CT-996 in obese patients, showing 7.3% weight loss (6.1% placebo-adjusted) after four weeks of treatment. Importantly, there were no treatment discontinuations, and according to the company the compound’s side effect profile is in-line with other similar molecules.